NCT00894634已完成1 期
A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 37 人开始时间: 2009年3月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 37
- 主要终点
- Log transformed values of AUCL and Cmax
研究概览
简要总结
The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12 yrs and adolescents aged 12 to <18 yrs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender
- •Symptomatic or asymptomatic children/adolescents as follows:
- •A prior diagnosis of allergic rhinitis and either symptomatic or asymptomatic at the time of entry in the study; or * Symptoms of an acute URI; or
- •No symptoms of an acute URI, but at risk for developing an acute URI as evidenced by the following frequency, crowding, and exposure criteria:
- •Frequency: a history of frequent URIs defined as greater than 6 infections/yr for children aged 2 to less than 6 yrs and as greater than 4 infections per year for adolescents aged 6 to less than 18 yrs;
- •Crowding: living in a home with greater than 4 persons, or sleeping in the same bedroom with greater than 3 persons;
- •Exposure: the presence of another family member in the household who is ill with a URI, or a child in the family that is attending preschool, or attending school with greater than 6 children in the class;
- •Except for allergic rhinitis or a URI, children/adolescents are in normal physical health (i.e., no clinically significant systemic disease) as judged by the Investigator upon physical examination of the subject;
- •Subjects do not require concomitant medication except for low-dose inhaled glucocorticoids for allergic rhinitis or mild concomitant asthma, if dose is stabilized before entry in the study (i.e., dose is not changed for one month prior to or during the study), and inhaled short-acting beta-2 adrenergic agonists for concomitant asthma, as needed;
- •Post menarchal females must be using a reliable method of contraception (i.e., oral, transdermal, injectable or implanted contraceptives, IUD, cervical cap, diaphragm, condom, abstinence, or surgical sterility).
排除标准
- •The child/adolescent weighs less than 24 pounds or is below the 5th or above the 95th percentiles in physical growth characteristics (i.e., height and weight), and BMI based on age and gender;
- •Inability to swallow the medication;
- •Eaten within 2 hours prior to dosing;
- •A known hypersensitivity to BROM, any other antihistamine, or EMLA cream;
- •Systolic and/or diastolic blood pressure at or above the 95th percentile based on gender, and age and height percentiles. (Note: If a subject with no history of hypertension has a blood pressure reading at or above the 95th percentile, the subject will be allowed to rest for 15 minutes and the blood pressure measurement repeated. Up to 3 consecutive measurements at approximately 5 min intervals will be allowed. Subjects who continue to have systolic and/or diastolic blood pressure readings at or above the 95th percentile will be excluded from the study);
- •History of melena or any hepatic, renal, endocrine (e.g., diabetes, thyroid disorder), cardiac, neurological, psychiatric, gastrointestinal, hematological or metabolic disorder deemed to be clinically significant by the Investigator;
- •Any serious medical condition or medical history felt by the Investigator to place them at increased risk;
- •The child is diagnosed with anemia or has a red blood cell count or hemoglobin level outside of normal range as evidenced by baseline hematology assessment;
- •Asthma symptoms at the time of entry in the study or requires medication other than allowed under Inclusion Criterion d;
- •Failure to comply with appropriate washout periods for any H-1 receptor antagonist treatment before and during the study, i.e., no use within 7 days of entering the study or at any time during the study, and no use of astemizole within the preceding 3 calendar months;
- •Other than described in Exclusion Criterion i, use of any medication 72 hours prior to dosing;
- •A history of drug, alcohol, or tobacco abuse (older children and adolescents), a history of Hepatitis B, a previous positive test for Hepatitis B surface antigen, or a previous positive Hepatitis C antibody;
- •A history of HIV infection or previous demonstration of HIV antibodies;
- •Female subjects who have experienced menarche and have a positive urine pregnancy test;
- •Parent/guardian/subject judged by the Investigator to be unable or unwilling to comply with the requirements of the protocol;
- •Have taken an investigational drug within 30 days prior to entering the study or have already participated in the trial;
- •Relative of the Sponsor, Investigator, or any personnel of the study site who are directly involved with the study.
研究组 & 干预措施
Brompheniramine maleate
Experimental
Brompheniramine maleate oral solution 1 mg/5 mL, single dose
干预措施: Brompheniramine maleate (Drug)
结局指标
主要结局
Log transformed values of AUCL and Cmax
时间窗: 72 hours
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study Evaluating Chlorpheniramine Maleate Liquid in Children and AdolescentsAllergic ReactionsNCT00837837Wyeth is now a wholly owned subsidiary of Pfizer36
已完成
1 期
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.HyperemiaNCT02039765Bausch & Lomb Incorporated12
已完成
1 期
Study of GSK3511294 in Healthy Chinese ParticipantsAsthmaNCT05140200GlaxoSmithKline20
已完成
1 期
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionModerate Hepatic ImpairmentNCT05610657Agios Pharmaceuticals, Inc.20
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese ParticipantsChronic Graft-versus-Host Disease (cGVHD)NCT05885451Amgen18